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detectable in 293/1934 (15%), while 216/1934 (11.2%) were considered unsuppressed (>200 48 copies/ml). The following factors were associated with an increased risk of unsuppressed viremia:
49 not having household electricity (adjusted prevalence rate ratio (aPRR) 1.74, 95% confidence 50 interval (CI) 1.28-2.36, p<0.001); self-reported missed cART doses (aPRR 1.63, 95% CI 1.24-51 2.13, p<0.001); recent hospitalization (aPRR 2.48, 95% CI 1.28-4.80, p=0.007) and experiencing 52 abnormal vaginal discharge in the last three months (aPRR 1.88; 95% CI 1.16-3.04, p=0.010). 
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Barriers to achieving the UNAIDS 2020 strategy regarding the 'third 90' persist in sub-Saharan 73 Africa in part due to suboptimal cART adherence (3) . In the absence of viral resistance, HIV viral 74 load assessment is the proxy for adherence, therefore the contributing factors to both adherence 75 and viremia may overlap. The most common factors identified as being associated with decreased 76 adherence include individual factors like younger age below 24 years, forgetting the dosing time, 77 depression, and substance use. The predominant contextual issue remains stigmatization and 78 disclosure [3] [4] [5] . Other factors such as length of time on ART, education, personal motivation to 79 start ART, satisfaction with health worker information availed were conducive to adherence [6-8].
80
Additionally, studies have shown that women who initiate cART for their own health display better 81 adherence as compared to women who initiate during pregnancy. Even then, adherence to cART 82 in the post-partum period tends to wane. This may be attributed to less motivation to protect the 83 child post-delivery and following cessation of breast feeding, as well as a possible break in 84 transition from postnatal to general HIV care [4, 5] .
85
Whereas the scale up of virologic monitoring in sub-Saharan Africa since 2013 has led to the 
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The PEPFAR-funded PROMOTE study presents a unique opportunity to assess longer term 100 treatment outcomes among women randomized in the PROMISE trial to initiate varied 101 antiretroviral (ARV) regimens during pregnancy for the purpose of preventing perinatal HIV 102 transmission and subsequently transitioned to lifelong cART following disease progression or in 103 response to the START study which showed clear benefit of universal ART in June 2015 (10).
104
The PROMOTE study approach provides data from current public sector HIV care provision mixed 105 with precise individualized clinical and laboratory data collected under trial settings. 
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Ethical considerations 147
The PROMOTE study was approved by all relevant institutional review boards (IRBs) in the U.S.
148
and participating African research sites/countries. All women provided written informed consent 149 to enroll and be followed up for the duration of the study with their children and agreed to provide 150 study samples for protocol lab safety assays, as well as for storage of blood and hair samples.
151

Statistical analysis 152
We analyzed baseline data from a multi-country cohort study to estimate the proportion of women all the baseline variables were associated with unsuppressed viremia >200 copies/ml (Table 1) .
184
Notably, the prevalence of unsuppressed viremia > 200 copies/ml was the highest (17.5%) in
185
Malawi compared to other countries. Of note, 24% of women with recent hospitalization had 186 unsuppressed viremia.
187 We found that 11% of the 1934 women initiated on antiretroviral treatment had unsuppressed copies threshold used by UNAIDS. We identify sociodemographic, self-reported non-adherence,
218
and clinical factors that were associated with detectable viremia > 200copies/ml.
220
The higher proportion of women with detectable viremia than the UNAIDS target suggests that 
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Based on self-reported adherence reports using the study questionnaire, we found that self-234 reported missed ART doses was significantly associated with unsuppressed viremia. Even though 235 there is uncertainty regarding the reliability of self-reported adherence, this measure of 236 adherence still remains as a cheap and easily determined mode of adherence monitoring in 237 resource limited settings using appropriate tools(5). We noted however that a small proportion of 238 women (9.7%) were not aware of the dosing instructions. This factor was not a significant predictor 
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The strengths in these analyses include that PROMOTE is one of the largest current longitudinal 293 cohort studies of HIV infected women of child bearing age in Africa; and is being conducted in multiple sites in East and Southern Africa, which increases the generalizability of the findings. In 295 addition, there is ongoing Quality Assurance and monitoring as part of the study. Relative 296 limitations to the analyses are that this is a baseline cross sectional analysis; and that data on 297 resistance are not currently available.
298
Future plans for the study 299 Follow up trends in viral load and adherence data over the 5 year follow up in PROMOTE will be 300 presented when available; as will the relation of hair drug levels and drug resistance testing 
